human papillomavirus vaccination (Gardasil)

ApprovedSmall molecule

human papillomavirus vaccination (Gardasil) is one of 43 small molecule programs targeting Papilloma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PapillomaActive, not recruiting

PapillomaApproved

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Papilloma

#DrugCompanyPhaseTrials

Cervarix

GSK

Phase 3

9 2

GSK 257049

GSK

Phase 3

6 3

Comparator: Pbo

Merck & Co.

Phase 3

3 4

Gardasil

Merck & Co.

Phase 3

11 5

Havrix

GSK

Phase 3

1 6

Engerix-B

GSK

Phase 3

1 7

Fludara

Sanofi

Phase 2

2 8

Taxol

Teva

Phase 2

2 9

Tecentriq

Roche

Phase 2

1 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Papilloma1 trial

Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study

Completed·TTuen Mun Hospital·Phase 4·NCT00911521·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for human papillomavirus vaccination (Gardasil). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — human papillomavirus vaccination (Gardasil) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for human papillomavirus vaccination (Gardasil). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tuen Mun Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTuen Mun Hospital

human papillomavirus vaccination (Gardasil)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Papilloma1 trial

References

Drug Info

Quick Facts

Related News